Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore...
25 KB (3,152 words) - 23:45, 23 June 2025
SGLT2 inhibitor (redirect from Gliflozins)
called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney)...
48 KB (4,794 words) - 12:53, 12 July 2025
treatment of type 2 diabetes. Gliflozins enhance glycemic control as well as reduce body weight and systolic and diastolic blood pressure. The gliflozins canagliflozin...
8 KB (957 words) - 22:12, 29 May 2025
inhibitors, also called gliflozins, are used in the treatment of type 2 diabetes. SGLT2 is only found in kidney tubules and in conjunction with SGLT1...
16 KB (1,628 words) - 18:49, 17 November 2024
GLP-1 receptor agonist (section Mechanism of action)
They are also in development for other indications, such as non-alcoholic fatty liver disease, polycystic ovary syndrome, and diseases of the reward system...
52 KB (5,425 words) - 15:03, 10 July 2025
Semaglutide (section Mechanism of action)
examining hormones secreted during eating, and testing them on pig pancreases, leading to the discovery of GLP-1's significant potency in 1988. Their...
80 KB (6,902 words) - 11:54, 5 July 2025
Kawamatsu Y, Fujita T, Meguro K, Ikeda H (November 2002). "[Discovery and development of a new insulin sensitizing agent, pioglitazone]". Yakugaku Zasshi...
6 KB (424 words) - 18:34, 28 May 2025
Tirzepatide (category Drugs developed by Eli Lilly and Company)
"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept". Molecular...
52 KB (4,248 words) - 14:47, 9 July 2025
N-terminal of the MPGF, but sequencing experiments of endogenous GLP-1 revealed a structure corresponding to proglucagon (78–107) from which two discoveries were...
29 KB (3,593 words) - 11:46, 25 May 2025
Sulfonylurea (section Treatment of type 2 diabetes)
Jeanmart S, Luksch T, Plant A (August 2013). "Current challenges and trends in the discovery of agrochemicals". Science. 341 (6147): 742–6. Bibcode:2013Sci...
25 KB (2,747 words) - 22:16, 29 May 2025
oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in...
21 KB (1,982 words) - 22:08, 29 May 2025
Insulin analogue (redirect from Insulin and its analog structure)
January 2021). "Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320". Journal of Medicinal Chemistry. 64 (1):...
76 KB (7,537 words) - 14:03, 19 June 2025
Pioglitazone (category Drugs developed by Eli Lilly and Company)
Retrieved 3 March 2019. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495. Archived from the original...
28 KB (2,661 words) - 18:48, 8 July 2025
Saroglitazar (section Mechanism of action)
serum creatinine was noted with 16 weeks use of saroglitazar at 4mg/day dose. In December 2016, Zydus Discovery DMCC, a research subsidiary Zydus Lifesciences...
9 KB (767 words) - 21:52, 3 March 2025
Diabetes medication (section Mechanisms of action)
Pharmacogenetics of new classes of antidiabetic drugs. Bosn J of Basic Med Sci. 2021. DOI: https://doi.org/10.17305/bjbms.2021.5646 "SGLT2 Inhibitors (Gliflozins) –...
52 KB (5,601 words) - 23:54, 3 July 2025
Metformin (redirect from Adverse effects of metformin)
Berthel S (2010). "Diabetes Drugs: Present and Emerging". Burger's Medicinal Chemistry and Drug Discovery. pp. 1–38. doi:10.1002/0471266949.bmc198....
158 KB (15,092 words) - 09:32, 12 July 2025
Buformin (section Mechanism of action)
ChemLDplus advanced database Ravina E, Kubinyi H (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. Wiley. p. 215. Miller...
21 KB (2,261 words) - 15:48, 9 December 2024
Rosiglitazone (section Society and culture)
Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495. Chen X, Yang L, Zhai SD (December 2012). "Risk of cardiovascular disease and all-cause...
58 KB (5,975 words) - 09:38, 12 July 2025
Diabetic ketoacidosis (category Complications of diabetes)
diabetes". Drugs in the gliflozin class (SGLT2 inhibitors), which are generally used for type 2 diabetes, have been associated with cases of diabetic ketoacidosis...
45 KB (5,146 words) - 08:18, 26 June 2025
Insulin (medication) (category Drugs developed by Eli Lilly and Company)
sur le rôle du pancréas dans l'assimilation nutritive | The Discovery and Early Development of Insulin". insulin.library.utoronto.ca. Archived from the original...
108 KB (11,453 words) - 07:28, 13 July 2025